HomeCompareSOLTF vs GBDC

SOLTF vs GBDC: Dividend Comparison 2026

SOLTF yields 37.88% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.64M in total portfolio value· pulled ahead in Year 5
10 years
SOLTF
SOLTF
● Live price
37.88%
Share price
$5.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$206.4K
Annual income
$33,329.74
Full SOLTF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — SOLTF vs GBDC

📍 GBDC pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSOLTFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SOLTF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SOLTF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SOLTF
Annual income on $10K today (after 15% tax)
$3,219.70/yr
After 10yr DRIP, annual income (after tax)
$28,330.28/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,954,793.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SOLTF + GBDC for your $10,000?

SOLTF: 50%GBDC: 50%
100% GBDC50/50100% SOLTF
Portfolio after 10yr
$10.53M
Annual income
$8,242,031.79/yr
Blended yield
78.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

SOLTF
No analyst data
Altman Z
0.7
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SOLTF buys
0
GBDC buys
0
No recent congressional trades found for SOLTF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSOLTFGBDC
Forward yield37.88%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$206.4K$20.85M
Annual income after 10y$33,329.74$16,450,733.83
Total dividends collected$152.8K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: SOLTF vs GBDC ($10,000, DRIP)

YearSOLTF PortfolioSOLTF Income/yrGBDC PortfolioGBDC Income/yrGap
1$14,488$3,787.88$12,492$1,791.70+$2.0KSOLTF
2$20,631$5,128.82$16,527$3,160.58+$4.1KSOLTF
3$28,901$6,825.67$23,588$5,904.90+$5.3KSOLTF
4$39,860$8,936.20$37,141$11,901.65+$2.7KSOLTF
5← crossover$54,169$11,518.54$66,205$26,463.38$12.0KGBDC
6$72,590$14,629.36$137,452$66,612.65$64.9KGBDC
7$95,993$18,321.84$342,372$195,298.53$246.4KGBDC
8$125,356$22,643.78$1,053,292$686,954.33$927.9KGBDC
9$161,767$27,635.79$4,111,439$2,984,416.95$3.95MGBDC
10$206,420$33,329.74$20,849,974$16,450,733.83$20.64MGBDC

SOLTF vs GBDC: Complete Analysis 2026

SOLTFStock

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Full SOLTF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this SOLTF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SOLTF vs SCHDSOLTF vs JEPISOLTF vs OSOLTF vs KOSOLTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.